Grail Stock

grail.comBioTechFounded: 2016Funding to Date: $2.02B

GRAIL is a healthcare company specializing in early cancer detection by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to developed a multi-cancer early detection blood test.

Enterprise Value (based on primary financings)

Register for Details

For more details on financing and valuation for Grail, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Grail investors also invested in these private companies

PSP Investments
Canada Pension Plan Investment Board
Sequoia Capital China
Hillhouse Capital Group
HuangPu River Capital

Team

Management Team

Hans Bishop
Chief Executive Officer & Board Member
Gautam Kollu
Chief Commercial Officer
Alex Aravanis Ph.D
Co-Founder, Chief Scientific Officer & Head of Research & Development
Aaron Freidin
Corporate Controller
Jeffrey Huber
Co-Founder & Vice Chairman
Kenneth Drazan MD
President
Matthew Young
Chief Financial Officer & Chief Operating Officer

Board Members

Brook Byers Ph.D
Catherine Friedman
Hal Barron
Hans Bishop
Jeffrey Huber
Kaye Foster
Maykin Ho Ph.D
Richard Klausner MD
Illumina
Robert Nelsen
ARCH Venture Partners
Vikram Bajaj Ph.D
Foresite Capital Management
William Rastetter Ph.D
Xiangmin Cui Ph.D
Decheng Capital

Other companies like Grail in the BioTech sector

Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.89B
Sector
Last Round Est. Valuation
$872.62MM
Sector
Last Round Est. Valuation
$486.63MM
Sector
Last Round Est. Valuation
$186.12MM
Sector
Last Round Est. Valuation
$50.4MM
Sector
Last Round Est. Valuation
$185MM
Sector
Last Round Est. Valuation
$289.42MM

News

European regulators called Illumina's decision to finalize its purchase of Grail "unprecedented" and said they could ultimately impose financial penalties.
Galleri is designed to detect more than 50 cancer types through a routine blood draw and, when a cancer signal is detected, predict its origin.
The cash-and-stock deal was announced in September last year by Illumina to gain access to Grail's flagship Galleri blood test used to diagnose cancers at early stages when the disease is easier to treat.